Background
Abstract Background
Pathogens causing acute fever, with the exception of malaria, remain largely unidentified in sub-Saharan Africa, given the local unavailability of diagnostic tests and the broad differential diagnosis.
Methodology/Principal Findings
We conducted a cross-sectional study including outpatient acute febrile syndromes in both children and adults, between November 2015 and June 2016 in Kinshasa, Democratic
Republic of Congo. Serological and molecular diagnostic tests for arboviral infections were performed on blood, including PCR and NS1-RDT for acute, and ELISA and IFAT for past infections.
Conclusions/Significance
Among 342 patients, aged 2 to 68 years, 45.3% tested positive on malaria Rapid Diagnostic Test. However, 87.7% received antimalarial and 64.3% antibacterial treatment. Further investigation among 235 fever cases revealed 19 (8.1%) acute dengue and 2 (0.9%) acute chikungunya infections, with an important proportion of participants already exposed to flaviviridae (possibly dengue) and alphaviridae (possibly chikungunya) in the past, namely 30.2 % and 26.4% respectively. We found no evidence of exposure to Zika nor yellow fever virus.
Introduction
Acute fever is one of the main reasons for healthcare seeking worldwide. In tropical settings, and especially sub-Saharan Africa, malaria is the first cause to be ruled out, which is done increasingly following the World Health Organization's testing before treating policy of 2010 -through microscopic blood slide examination or rapid diagnostic test (RDT).
Following the introduction of this policy, together with the roll out of the highly efficacious artemisinin-combination as first-line malaria treatment and efficacious vector control, the overall malaria burden declined over the last decade. Accordingly, clinicians face a relatively higher number of malaria-negative patients for whom they do not have a clear diagnosis (1) (2) (3) . In sub-Saharan Africa, where healthcare settings are often resource-limited, healthcare providers face the daunting challenge pinpointing the causing agent of these febrile illnesses in an adequate and timely fashion, with little to no diagnostic means other than a malaria-RDT. They mostly rely on history taking and physical examination to determine the focus and cause of infection, of which acute respiratory infection (ARI), gastroenteritis (GE) and urinary tract infection (UTI) are the three most prevalent syndromes reported. However, for over more than half of the patients presenting with acute fever, no focus can be found at all and clinicians label them as 'undifferentiated'-knowing that their differential diagnosis is broad, ranging from viral, bacterial, parasitic to fungal infections. Although viral illnesses are often suspected, prescription of antimicrobials is rampant in this group (4) and their licentious usage in low-resource settings fuels the global burden of antimicrobial resistance (5-7). Thus more insight in the exact causes of this group of 'undifferentiated fevers' may help curb the usage of antimicrobials and improve the clinical care of patients in low-resource settings more broadly. Still, evidence on the causes of 'undifferentiated acute fever syndromes' is scarce and is coming from inpatient settings.
To our knowledge, only one study in sub-Saharan Africa (Sierra Leone) looked in a prospective way to etiologies of acute undifferentiated fever in all age groups at an outpatient, primary health care level and found a 5% dengue virus (DENV) infection rate and a 39% acute chikungunya virus (CHIKV) or related alphavirus infection rate (8) .
Nonetheless, limited outbreaks and sporadic clinical cases of DENV have been reported over the last 50 years in 22 African countries (9) . Seroprevalence studies have demonstrated DENV IgG-antibodies, indicating past-infection, in 12.5% of study participants in Cameroon, 36% in Burkina Faso and 45% in Nigeria (9) , although in other areas seropositivity remained zero (10) . In Tanzania past infection rates are higher, reaching 50.6% in health-facility based studies and 11% in community-based studies (11) . Despite the presence of all four DENV serotypes, severe disease epidemics are rarely reported in Africa (12) . The DENV burden in Africa is, based on modeling, estimated at 16 million symptomatic clinical infections or 16% of the global total (13) . In East-Africa, CHIKV outbreaks and circulation are described, such as in Kenya with a past-infection rate of 67% (14) and the reports of epidemics in 2004 in Kenya (15) , in 2013 in Tanzania (16) and in 2018 in Mozambique (17) .
In the Central African region, DENV, CHIKV, yellow fever (YFV) and Zika virus (ZIKV) -all leading causes of acute fever in other (sub)tropical regions -are circulating too. This is illustrated by CHIKV outbreaks in Kinshasa in 2000 (18) and 2012 (18bis) and Brazzaville in 2011 (19) , and the 2013 DENV (20) and 2012 when testing samples negative for YFV (28) .
In this study in DRC, we aim to quantify the importance of arboviruses as a cause of acute febrile syndromes. Furthermore, we aim to describe the case presentation and the presence of arbovirus/malaria co-infections.
Methods

Setting
The study took place in Lisungi Health center in Pumbu, an area of about 14,000 inhabitants, belonging to the peri-urban health district Mont Ngafula 1, at the southern side of 
Study design and participants
The study was designed as a cross-sectional study with prospective patient inclusion.
As the proportion of pathogens can change over time, especially for epidemic-prone diseases, we included patients proportionally from November 2015 to June 2016 and limited patient inclusion of undifferentiated fever to 6 per day (3 children and 3 adults). Only patients of at least 2 years old, presenting at the outpatient department with a history of acute fever (i.e. ≥ 2 days and ≤ 7 days) or having an axillary temperature of ≥ 37.5°C, were eligible. Patients with any history of an acute injury, trauma or poisoning, suspicion of meningitis/encephalitis, recent hospitalization or giving birth in the preceding two weeks, were excluded. Reported recent intake of antimicrobials was not an exclusion criterion, but was recorded accordingly.
Given the non-specificity of the signs and symptoms of a possible arboviral infection, and in order to estimate the burden of co-infection, we included a subsample of patients with acute respiratory infection (ARI), gastroenteritis (GE) and urinary tract infection (UTI) categorized on clinical grounds or with confirmed malaria based on laboratory analysis. Only 1 child and 1 adult per day could be recruited from these latter three 'differentiated fevers' groups, in addition to the aforementioned maximum of 6 undifferentiated fever cases per day, in order to overcome selection bias. Our main interest was the distribution of viral pathogens among the undifferentiated fevers. To be able to detect the presence of a disease whose prevalence is 5% with a precision of 2.5% at a confidence level of 95%, 290 patients with 'undifferentiated fever' needed to be included. Increased with 10% for incomplete data or loss of biological samples, we came to a sample size of 320.
Data collection Case Report Form
For every participant, a pre-tested case report form (CRF) was filled out, based on a standardized clinical history and physical examination by one of the four physicians/clinical officers on ground, following standard clinical practice. Prior to the start of study, the clinicians received a training on the inclusion algorithm and CRF. Patient management was done according to local guidelines. For every patient the following information was recorded: demographic data (age, sex, residence), past medical history (yellow fever vaccination, intake of antimicrobials), signs and symptoms, duration of fever, medical examination, diagnosis and treatment given.
Laboratory analyses
In the on-site laboratory of the Lisungi health center, capillary blood was taken to microscopically count the number of leukocytes and a thin smear stained with Giemsa was done for differentiation. Hematocrit and hemoglobin were determined using a portable spectrophotometer (Hemocontrol, EKF Diagnostics, Barleben, Germany). Furthermore, malaria and dengue were diagnosed by the HRP2/pLDH RDT SD Bioline® Malaria Ag Pf/Pan 05FK60 and RDT SD Bioline® Dengue Duo 11FK46 respectively. The latter is an immunochromatographic one-step assay designed to detect both DENV NS1 antigen (present in first week of infection) and IgM/IgG antibodies (detectable from the fifth day of fever onwards) to DENV. HIV was not routinely tested for, given the overall low prevalence in the study area and the unavailability of HIV antiretroviral treatment according to national ethics guidelines in this setting.
All undifferentiated fevers, together with about half of both the malaria positives and the clinically apparent differentiated fevers -identified through random selection, were tested for arbovirus exposure. For this purpose serum and EDTA whole blood were stored in liquid 
Results
Over the period November 2015 to June 2016, 342 patients were included from whom clinical data and on the spot malaria-RDT results were recorded. Clinical diagnoses were as follows: 70.2% undifferentiated fever, 6.7% UTI, 6.1% GE and 17.0% ARI -all three further labeled as 'clinically apparent differentiated fevers'. The study population (Table 1) consisted of 183 (53.5%) female participants and 180 (53.1%) were under the age of 18. Fifty (14.6%) patients were in need of hospitalization. The reported YFV vaccination rate was as low as 1%. The vast majority (77.8%) of the patients presented in the four first days after the onset of fever, with relatively nonspecific signs and symptoms (Table 2) . Malaria RDT was positive in 155 (45.3%) of the participants. However, 300 (87.7%) received an antimalarial treatment. Antibacterials were frequently prescribed: 64.3% of participants received at least one and 11.7% received even more than one antibacterial drug. With regard to the clinical presentation of both DENV and CHIKV infections, we found no specific signs or symptoms to be statistically significantly -let alone clinically relevant -associated with acute DENV or CHIKV versus the other febrile patients (S1 Table) . None of the acute DENV or CHIKV cases were severe, none were hospitalized and there was no apparent leucopenia or hemoconcentration (as often seen in severe DENV cases).
We found 71 (30.2%) patients with evidence for past DENV infection (ELISA-IgG positive), of which 60 (75%) contained relatively high levels of anti-flavivirus antibody (ratio ≥ 1.9), the latter not depending on age (data not shown). The PRNT on the subsample was only positive in 5.6% and 66.7% for DENV, and 25% and 20% for YFV, on samples with
IgG ratio below 1.9 and above 1.9 respectively. For these past infections, all 4 serotypes were detected: DENV1, DENV2, DENV3 and DENV4 in 4, 2, 1 and 1 patient respectively (of the 6 positively tested DENV PRNT) -two patients were reactive to all 4 serotypes, the other 4 only to 1 serotype. Past exposure to CHIKV was confirmed with IFAT IgG in 26.4% of the study participants. When taking past DENV and CHIKV together, 56.6% of the study participants were exposed to at least one and 11.9% to both arboviruses. The prevalence of past DENV and CHIKV infections increased with age, raising from 18.9% and 5.4% under 5 years of age, to 80% and 40% over 65 years of age, respectively (Fig 1) . The association of age is statistically significant for the past infections with CHIKV (p=0.01) and DENV (p<0.01) (S2 Table) . Having been exposed to DENV was also statistically significant associated with recent travel (p=0.02). The congruence between the RDT and PCR/ELISA results for DENV was variable: in comparison to PCR the sensitivity of NS1 was 90%, in comparison to IgM ELISA the IgM RDT had a sensitivity of 30% and in comparison to IgG ELISA the IgG RDT had a sensitivity of 7.6%. The specificities were all above 99.3%. Importantly, neither DENV nor CHIKV was clinically suspected or was considered in the clinical differential diagnosis and 64.3% of patients were treated with at least one antibacterial drug, of whom almost one in six (11.7%) received dual or triple antimicrobial therapy. A possible explanation of the apparent absence of clinical and/or severe DENV cases in our study, but also in other African settings, is that African heritage genetically protects against severe DENV, more specifically the lower OSBPL10 expression profile in Africans is protective against viral hemorrhagic fever and dengue shock syndrome (31, 32) .
We used DENV ELISA tests on all samples. Although it is widely known that there is cross-reactivity among flaviviruses, ELISA is still the most affordable -hence most commonly used -test (24) . Since YFV vaccination is an expected cause of cross-reactions, we performed PRNT for DENV and YFV in a subset of samples, and found that the congruence between DENV ELISA and PRNT was lower than in American and Asian settings (33) (34) (35) (36) (37) . A similar observation was made in another study in DRC with a certain level of discordance between ELISA and PRNT (38) , and in a study in Ethiopia where crossreaction and low confirmation by PRNT was also shown (39) . In our study, the majority of the samples negative with DENV PRNT was also negative with PRNT for YFV, which indicates that the high flavivirus IgG positivity was not due to YFV vaccination. A plausible explanation can be that in DRC other flaviviruses circulate, which cause the aforementioned cross-reaction in ELISA (40) . Similarly, the results of CHIKV serology could be the result of cross-reaction with other togaviruses, but this is very unlikely in DRC as Mayaro is only present in South America, and there is no apparent circulation of o'nyong nyong, Semliki Forest and Sindbis virus. YFV was detected in mosquitoes collected in Kinshasa a year before our study (23) and was actively circulating in the region at the time of study, transgressing the border with Angola (21), but we did not detect any acute case. The report of YFV vaccination was very low (below 1%), but as YFV vaccination is included in the childhood vaccination program over the last decade, this may indicate that the population is not aware of which vaccines their children get. However, the increasing prevalence of flavivirus IgG antibodies with age is congruent with a history of increasing exposure to the pathogens over lifetime and thus was in this study not explained by YFV vaccination. ZIKV
was not suspected to be circulating in the area and indeed, no positive case was found in the subsample tested.
In a recent study conducted in the same area in Kinshasa, it was reported that 62% of patients with acute fever had neither malaria nor unspecified bacterial infection (41) . For the first time we were able to demonstrate the fact that arboviruses, more specifically DENV and CHIKV, circulate in high numbers in the capital of DRC. The highest number of cases were reported in the dry season, but cases were also confirmed in the other months, indicating that transmission is not only happening in epidemics, but that there is a year-round circulation.
This contradicts the existing paradigm that arbovirus infections are outbreak-driven in Africa and are not endemic, as is the case in Asia and Latin America. Our study adds to mountingbut still scarce -evidence that arboviruses are endemic in large parts of Africa (17) .
Although the sampling design of this study was adequate to evaluate the proportion of arboviruses causing acute febrile syndromes, sample size was small and patients were only recruited from a single health center. However, the Lisungi health center is well visited by the surrounding population and all ages were represented in our study population. Moreover, the median age of our study population is 17 years, which approximates the median age of 18.6 years in the DRC (UNDESA 2017 and CIA World Factbook 2017).
The discrepant results between CHIKV ELISA and IIFT were at least partly explained by the cross-reaction with actual malaria infection, a phenomenon which has been described before for ZIKV (42) . Furthermore, we were able to document the common practice of overprescription of antimalarial drugs in malaria RDT-negative patients, as is apparently the case nationwide in DRC as recently shown by Ntamabyaliro et al (43) . Indeed, while not even half of the patients tested positive for malaria, almost 90% received antimalarial treatment, in addition to 16% of patients treated with over-the-counter antimalarials prior to presentation at the clinic, which brings the total close to 100%. It could be questioned whether the rigorous implementation and usage of RDTs has any added benefit. A recent meta-analysis evaluating data from over half a million children and adults, showed that the introduction of a malaria RDT simply shifted the antimicrobial overuse from one antimicrobial class to the other, mainly from antimalarial to antibacterial and anthelmintic drugs (44) . Consequently, the increasing prescription rate of antimicrobials -including antibacterial, anthelmintic and antimalarial drugs, is extremely worrisome in terms of the growing global problem of antimicrobial resistance, including against Plasmodium falciparum.
We did not investigate bacterial causes of fever through culture of blood or other bodily fluids, a test typically done in hospital settings, hereby possibly underestimating the burden of concomitant bacterial (super)infection. We therefore encourage further research elucidating the broad range of pathogens causing febrile illness and the distribution of the vectors involved in arboviral infections in urban and rural sub-Saharan African settings.
Based on our findings, we recommend to include arboviral infections, namely DENV and CHIKV, in the differential diagnoses of acute fever presentation in sub-Saharan Africa.
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